News and events
closerlook and Target ClarityTM recognized in PharmaVOICE’s first annual Innovation Issue
PharmaVOICE – April 2015
In April 2015, PharmaVOICE launched its first annual Innovation Issue, dedicated to recognizing groundbreaking organizations and developments in the pharma world. This year’s issue featured innovators ranging from household names to startups, and we’re pleased to announce that closerlook and our predictive modeling tool TargetClarityTM were counted among them.
As part of our robust CRM suite of product Offerings, TargetClarityTM was created to address a growing need we saw in pharma marketing—the need for a research approach that can help companies turn information into action. The pharmaceutical industry is experiencing an unprecedented increase in data, and digital marketers are looking for more effective ways to gain meaningful insight about their customers. That’s where TargetClarityTM comes in, enabling our clients to proactively target customers with the greatest untapped potential to prescribe a brand.
Whereas in the past, pharma analytics have been based on past prescribing behavior, TargetClarityTM offers insight into the capacity of individual HCPs to prescribe a particular product—whether they have reached their full prescribing potential or have room to grow. This kind of predictive insight also helps marketers reach customers with messages and services that are most likely to be relevant to them.
For example, one brand was able to use TargetClarityTM to find HCPs with the same characteristics as their current highest-writing prescribers, and then reach out to those new HCPs through the appropriate digital channel. This enabled the brand to increase exposure to HCPs who had been previously overlooked.
And to us, that’s the key. Companies know more about their customers than ever before—and better targeting with tools like TargetClarityTM helps get the right brands into the hands of HCPs most likely to prescribe them to the patients that need them the most.
The drugs, Optistavin, Easovartis and Librylin, and names, results, case studies and specific information, referenced in this advertisement are fictional and were created solely for illustrating the digital marketing capabilities of closerlook, inc. Any resemblance to actual drugs, medications, treatments, persons, living or dead, or to actual events, is purely coincidental. closerlook, inc. does not assume and hereby disclaims any liability to any party for any loss, damage or disruption caused by such party’s reliance on the fictitious information contained in this illustration.